Department of Biomedicine, University of Basel, Basel, Switzerland.
Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Front Immunol. 2020 Sep 29;11:571951. doi: 10.3389/fimmu.2020.571951. eCollection 2020.
Tumor-associated microglia (MG) and macrophages (MΦ) are important components of the glioblastoma (GBM) immune tumor microenvironment (iTME). From the recent advances in understanding how MG and GBM cells evolve and interact during tumorigenesis, we emphasize the cooperation of MG with other immune cell types of the GBM-iTME, mainly MΦ and T cells. We provide a comprehensive overview of current immunotherapeutic clinical trials and approaches for the treatment of GBM, which in general, underestimate the counteracting contribution of immunosuppressive MG as a main factor for treatment failure. Furthermore, we summarize new developments and strategies in MG reprogramming/re-education in the GBM context, with a focus on ways to boost MG-mediated tumor cell phagocytosis and associated experimental models and methods. This ultimately converges in our proposal of novel combinatorial regimens that locally modulate MG as a central paradigm, and therefore may lead to additional, long-lasting, and effective tumoricidal responses.
肿瘤相关的小胶质细胞(MG)和巨噬细胞(MΦ)是胶质母细胞瘤(GBM)免疫肿瘤微环境(iTME)的重要组成部分。从最近对 MG 和 GBM 细胞在肿瘤发生过程中如何进化和相互作用的理解进展中,我们强调了 MG 与 GBM-iTME 中的其他免疫细胞类型(主要是 MΦ 和 T 细胞)的合作。我们全面概述了目前用于治疗 GBM 的免疫治疗临床试验和方法,但总体而言,低估了抑制性 MG 的拮抗作用,这是治疗失败的主要因素。此外,我们总结了 GBM 背景下 MG 重编程/再教育的新发展和策略,重点介绍了增强 MG 介导的肿瘤细胞吞噬作用的方法,以及相关的实验模型和方法。这最终集中在我们提出的局部调节 MG 作为中心范例的新组合方案上,因此可能会导致额外的、持久的和有效的杀肿瘤反应。